Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...

Cash position -- $15 million in cash and cash equivalents as of March 31, 2026, with potential for up to $20.2 million in ...

Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, ...

Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending a new oral treatment for people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The ...

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...